Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
The biopharma industry outlook on 2024: Guarded optimism for a …
Published Jan. 16, 2024. Ned Pagliarulo Lead Editor. Brian Tucker / BioPharma Dive. Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a ...
The golden era of GLP-1 drugs: Where we are and what comes next
Sep 23, 2024 · Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) are entero-pancreatic hormone-based treatments first approved in 2005 for type 2 diabetes (T2D). They are now commonly prescribed for weight loss and reduction of atherosclerotic cardiovascular (CV) risk in patients with T2D. The health benefits and market success of GLP-1 drugs are a hot ...
Meso Scale Discovery (MSD): An immunoassay platform with …
Feb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . …
Two decades and $200 billion: AbbVie’s Humira monopoly nears …
Mar 17, 2022 · All told, AbbVie filed about 250 patent applications for Humira in the U.S., 90% of them following the drug's 2002 approval, according to the advocacy group Initiative for Medicines, Access & Knowledge. One hundred and thirty have been granted. The strengthened patent shield has stretched AbbVie's legal monopoly in the U.S. for six years beyond the expiration of …
10 clinical trials to watch in the first half of 2024
Jan 2, 2024 · Moderna and Pfizer both reported promising results in early testing last fall and have moved on to late-stage studies. Moderna appears positioned to get to the finish line first. Results from its Phase 3 trial could be coming in the first half of this year, according to a federal database. — Delilah Alvarado.
Radiopharmaceuticals for cancer: Making radiation precise
Aug 15, 2023 · When the Food and Drug Administration approved a new prostate cancer drug last year, it validated a bet made by Novartis to acquire the drug’s maker, Endocyte. The decision was also another step forward for a long-studied research field that appears to finally be coming of age. The medicine, Pluvicto, is known as a “radiopharmaceutical.”.
Novartis wins FDA approval for new heart drug, but faces uphill …
Dec 22, 2021 · Novartis priced Leqvio at $3,250 per dose for U.S. sale, meaning the first year of treatment will cost $9,750 and subsequent years $6,500. That’s slightly higher than the $5,400-per-year price that the Institute for Clinical and Economic Review, a watchdog group on drug costs, said would be cost effective for Leqvio when used broadly, but ...
Biotech News - BioPharma Dive
5 days ago · A new biotech, built around protein design, springs from David Baker’s lab. Archon Biosciences, co-founded by the winner of the 2024 Nobel Prize in Chemistry, emerged from stealth Wednesday with $20 million in seed capital. By Gwendolyn Wu • Oct. 30, 2024.
Takeda targets ‘efficiency’ in restructuring, pipeline cuts
May 9, 2024 · Takeda estimates it will incur about $900 million in restructuring costs during the coming fiscal year, which runs from April to March. The company aims to to improve its core operating profit margin by 1% to 2.5% each year from 2025 on, targeting an eventual range in the low-to-mid 30%. The arrival of lookalike competition to AbbVie’s Humira ...